These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 17360630)

  • 1. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.
    Polo JM; Juszczynski P; Monti S; Cerchietti L; Ye K; Greally JM; Shipp M; Melnick A
    Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3207-12. PubMed ID: 17360630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.
    Juszczynski P; Chen L; O'Donnell E; Polo JM; Ranuncolo SM; Dalla-Favera R; Melnick A; Shipp MA
    Blood; 2009 Dec; 114(26):5315-21. PubMed ID: 19855081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
    Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
    Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.
    Ci W; Polo JM; Cerchietti L; Shaknovich R; Wang L; Yang SN; Ye K; Farinha P; Horsman DE; Gascoyne RD; Elemento O; Melnick A
    Blood; 2009 May; 113(22):5536-48. PubMed ID: 19307668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.
    Pasqualucci L; Migliazza A; Basso K; Houldsworth J; Chaganti RS; Dalla-Favera R
    Blood; 2003 Apr; 101(8):2914-23. PubMed ID: 12515714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.
    Cerchietti LC; Yang SN; Shaknovich R; Hatzi K; Polo JM; Chadburn A; Dowdy SF; Melnick A
    Blood; 2009 Apr; 113(15):3397-405. PubMed ID: 18927431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.
    Ding J; Dirks WG; Ehrentraut S; Geffers R; MacLeod RA; Nagel S; Pommerenke C; Romani J; Scherr M; Vaas LA; Zaborski M; Drexler HG; Quentmeier H
    Haematologica; 2015 Jun; 100(6):801-9. PubMed ID: 25769544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.
    Duan S; Cermak L; Pagan JK; Rossi M; Martinengo C; di Celle PF; Chapuy B; Shipp M; Chiarle R; Pagano M
    Nature; 2012 Jan; 481(7379):90-3. PubMed ID: 22113614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
    Cardenas MG; Yu W; Beguelin W; Teater MR; Geng H; Goldstein RL; Oswald E; Hatzi K; Yang SN; Cohen J; Shaknovich R; Vanommeslaeghe K; Cheng H; Liang D; Cho HJ; Abbott J; Tam W; Du W; Leonard JP; Elemento O; Cerchietti L; Cierpicki T; Xue F; MacKerell AD; Melnick AM
    J Clin Invest; 2016 Sep; 126(9):3351-62. PubMed ID: 27482887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.
    Cerchietti LC; Hatzi K; Caldas-Lopes E; Yang SN; Figueroa ME; Morin RD; Hirst M; Mendez L; Shaknovich R; Cole PA; Bhalla K; Gascoyne RD; Marra M; Chiosis G; Melnick A
    J Clin Invest; 2010 Dec; 120(12):4569-82. PubMed ID: 21041953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma.
    Saito M; Novak U; Piovan E; Basso K; Sumazin P; Schneider C; Crespo M; Shen Q; Bhagat G; Califano A; Chadburn A; Pasqualucci L; Dalla-Favera R
    Proc Natl Acad Sci U S A; 2009 Jul; 106(27):11294-9. PubMed ID: 19549844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.
    Jiao J; Lv Z; Zhang P; Wang Y; Yuan M; Yu X; Otieno Odhiambo W; Zheng M; Zhang H; Ma Y; Ji Y
    Neoplasia; 2020 Mar; 22(3):142-153. PubMed ID: 32062068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.
    Parekh S; Privé G; Melnick A
    Leuk Lymphoma; 2008 May; 49(5):874-82. PubMed ID: 18452090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma.
    Ying CY; Dominguez-Sola D; Fabi M; Lorenz IC; Hussein S; Bansal M; Califano A; Pasqualucci L; Basso K; Dalla-Favera R
    Nat Immunol; 2013 Oct; 14(10):1084-92. PubMed ID: 23974956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas.
    Malpeli G; Barbi S; Moore PS; Scardoni M; Chilosi M; Scarpa A; Menestrina F
    Haematologica; 2004 Sep; 89(9):1091-9. PubMed ID: 15377470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.
    Franco R; Scognamiglio G; Valentino E; Vitiello M; Luciano A; Palma G; Arra C; La Mantia E; Panico L; Tenneriello V; Pinto A; Frigeri F; Capobianco G; Botti G; Cerchia L; De Chiara A; Fedele M
    Oncotarget; 2016 Sep; 7(37):59158-59172. PubMed ID: 27494852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential transcription factor targeting for diffuse large B-cell lymphomas.
    Cerchietti LC; Polo JM; Da Silva GF; Farinha P; Shaknovich R; Gascoyne RD; Dowdy SF; Melnick A
    Cancer Res; 2008 May; 68(9):3361-9. PubMed ID: 18451163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma.
    Chaganti SR; Chen W; Parsa N; Offit K; Louie DC; Dalla-Favera R; Chaganti RS
    Genes Chromosomes Cancer; 1998 Dec; 23(4):323-7. PubMed ID: 9824205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells.
    Ranuncolo SM; Polo JM; Melnick A
    Blood Cells Mol Dis; 2008; 41(1):95-9. PubMed ID: 18346918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma.
    Saito M; Gao J; Basso K; Kitagawa Y; Smith PM; Bhagat G; Pernis A; Pasqualucci L; Dalla-Favera R
    Cancer Cell; 2007 Sep; 12(3):280-92. PubMed ID: 17785208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.